Fc Receptor Signaling in Vaccine Design for the Elderly
Project Number5R01AI062917-02
Contact PI/Project LeaderZHENG, BIAO
Awardee OrganizationBAYLOR COLLEGE OF MEDICINE
Description
Abstract Text
DESCRIPTION (provided by applicant): In the elderly, there is a significant decline in both cellular and humoral immunity, leading to a state of dysregulated immune functions, or immunosenescence. Immunosenescence compromises protection against infectious diseases and contributes to the increased susceptibility of the elderly to infection. Furthermore, immunosenescence is responsible for the diminished responsiveness of the elderly to vaccination. Thus, the elderly are particularly vulnerable and are at greater risk in the event of a bioterror attack. An impaired response to influenza virus infection and vaccination in the elderly may be clinically most relevant. The responses to influenza vaccination are significantly impaired in aged people. Both primary and secondary antibody responses to influenza vaccination are diminished in the elderly. Even when the antigenic match between influenza vaccine and circulating virus is close, vaccination provides protection for only 30%- 40% of subjects aged >= 65 years, compared with 70-90% of those aged < 65 years. The currently available trivalent inactivated influenza vaccines are particularly ineffective in preventing deaths among elderly persons with associated chronic conditions, underscoring the need for influenza vaccines that are more effective in elderly persons who need them most.
Fc receptors (FcR) link the humoral and cellular branches of the immune system and have crucial functions in the activation and modulation of immune responses. Our recent studies indicate that immunization with immune complexes (IC) can correct the age-related deficiency in humoral and cellular immune responses to model antigens as well as influenza vaccines in mice. We have also demonstrated that the inhibitory Fc receptor, Fcgamma IIB, can be selectively ablated by RNA interference using small interfering RNA (siRNA). Thus, manipulating FcR signaling and vaccination with IC may constitute a novel immunization strategy to provide effective protection to immune compromised elderly population against influenza infection. In this project, we propose the following specific aims:
Aim 1. Determine the mechanisms by which immune responses are regulated by IC
Aim 2. Study the modulation of immune responses by selective signaling Fc receptors
Aim 3. Determine the effectiveness of 1C vaccines in overcoming age-related immune deficiency.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
01-June-2005
Project End Date
28-February-2010
Budget Start Date
01-March-2006
Budget End Date
28-February-2007
Project Funding Information for 2006
Total Funding
$366,188
Direct Costs
$244,125
Indirect Costs
$122,063
Year
Funding IC
FY Total Cost by IC
2006
National Institute of Allergy and Infectious Diseases
$366,188
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI062917-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI062917-02
Patents
No Patents information available for 5R01AI062917-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI062917-02
Clinical Studies
No Clinical Studies information available for 5R01AI062917-02
News and More
Related News Releases
No news release information available for 5R01AI062917-02
History
No Historical information available for 5R01AI062917-02
Similar Projects
No Similar Projects information available for 5R01AI062917-02